Dear provider of pharmaceutical services,

At PharmPix we are committed to the health and well-being of patients. The clinical team wants to communicate you with the latest up-to-date information on drug safety. It is for this reason that we are notifying you that on March 19, 2020, the US Food and Drug Administration (FDA) published a safety communication regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) for the novel coronavirus COVID-19. In their communication, the FDA states that they are aware of news reports stating the use of NSAIDs could worsen COVID-19 disease. However, currently, the FDA is NOT aware of scientific evidence connecting the use of NSAIDs with worsening COVID-19 symptoms. The FDA is investigating this issue and more information will be communicated when available.

Recommendations for healthcare professionals:

- Provide education to patients who wish to use treatment options other than NSAIDs regarding different over the counter (OTC) and prescription medications FDA-approved for pain relief and fever reduction.
- Advise patients and/or caregivers to speak to their healthcare professional if they are concerned about taking NSAIDs and rely on these medications to treat chronic diseases.
- Encourage patients and/or caregivers to read the full Drug Facts Label on OTC medications prior to use.
- Report adverse events or side effects to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

Additional information can be found at the FDA’s Drug Safety and Availability portal (https://www.fda.gov/drugs/drug-safety-and-availability).

Best regards,

PharmPix Clinical Department

Reference: